Repligen Corporation RGN.F Stock
Repligen Corporation Price Chart
Repligen Corporation RGN.F Financial and Trading Overview
Repligen Corporation stock price | 163.5 EUR |
Previous Close | 147 EUR |
Open | 145.4 EUR |
Bid | 145.6 EUR x 19000 |
Ask | 148.6 EUR x 19000 |
Day's Range | 145.4 - 145.4 EUR |
52 Week Range | 130 - 250 EUR |
Volume | 23 EUR |
Avg. Volume | 3 EUR |
Market Cap | 8.1B EUR |
Beta (5Y Monthly) | 1.064788 |
PE Ratio (TTM) | 53.45588 |
EPS (TTM) | 0.69 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 282.5 EUR |
RGN.F Valuation Measures
Enterprise Value | 8.18B EUR |
Trailing P/E | 53.45588 |
Forward P/E | 48.145695 |
PEG Ratio (5 yr expected) | 2.94 |
Price/Sales (ttm) | 10.408734 |
Price/Book (mrq) | 4.1694145 |
Enterprise Value/Revenue | 10.513 |
Enterprise Value/EBITDA | 35.872 |
Trading Information
Repligen Corporation Stock Price History
Beta (5Y Monthly) | 1.064788 |
52-Week Change | 13.16% |
S&P500 52-Week Change | 20.43% |
52 Week High | 250 EUR |
52 Week Low | 130 EUR |
50-Day Moving Average | 148.42 EUR |
200-Day Moving Average | 171.27 EUR |
RGN.F Share Statistics
Avg. Volume (3 month) | 3 EUR |
Avg. Daily Volume (10-Days) | 2 EUR |
Shares Outstanding | 55.68M |
Float | 51.89M |
Short Ratio | N/A |
% Held by Insiders | 6.76% |
% Held by Institutions | 97.79% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 21.57% |
Operating Margin (ttm) | 22.31% |
Gross Margin | 55.60% |
EBITDA Margin | 29.30% |
Management Effectiveness
Return on Assets (ttm) | 4.40% |
Return on Equity (ttm) | 9.05% |
Income Statement
Revenue (ttm) | 777.8M EUR |
Revenue Per Share (ttm) | 14.01 EUR |
Quarterly Revenue Growth (yoy) | -11.50% |
Gross Profit (ttm) | 455.71M EUR |
EBITDA | 227.95M EUR |
Net Income Avi to Common (ttm) | 167.82M EUR |
Diluted EPS (ttm) | 2.72 |
Quarterly Earnings Growth (yoy) | -38.60% |
Balance Sheet
Total Cash (mrq) | 618.02M EUR |
Total Cash Per Share (mrq) | 11.1 EUR |
Total Debt (mrq) | 420.7M EUR |
Total Debt/Equity (mrq) | 21.68 EUR |
Current Ratio (mrq) | 2.514 |
Book Value Per Share (mrq) | 34.873 |
Cash Flow Statement
Operating Cash Flow (ttm) | 160.12M EUR |
Levered Free Cash Flow (ttm) | 15.41M EUR |
Profile of Repligen Corporation
Country | Germany |
State | MA |
City | Waltham |
Address | Building 1 |
ZIP | 02453 |
Phone | 781 250 0111 |
Website | https://www.repligen.com |
Industry | Medical Instruments & Supplies |
Sector(s) | Healthcare |
Full Time Employees | 2025 |
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Q&A For Repligen Corporation Stock
What is a current RGN.F stock price?
Repligen Corporation RGN.F stock price today per share is 163.5 EUR.
How to purchase Repligen Corporation stock?
You can buy RGN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Repligen Corporation?
The stock symbol or ticker of Repligen Corporation is RGN.F.
Which industry does the Repligen Corporation company belong to?
The Repligen Corporation industry is Medical Instruments & Supplies.
How many shares does Repligen Corporation have in circulation?
The max supply of Repligen Corporation shares is 55.84M.
What is Repligen Corporation Price to Earnings Ratio (PE Ratio)?
Repligen Corporation PE Ratio is 236.95653000 now.
What was Repligen Corporation earnings per share over the trailing 12 months (TTM)?
Repligen Corporation EPS is 0.69 EUR over the trailing 12 months.
Which sector does the Repligen Corporation company belong to?
The Repligen Corporation sector is Healthcare.